The combination of TRAIL and luteolin enhances apoptosis in human cervical cancer HeLa cells
- 1 August 2005
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 333 (3) , 833-838
- https://doi.org/10.1016/j.bbrc.2005.05.179
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 18 references indexed in Scilit:
- Mechanisms of resistance to TRAIL-induced apoptosis in cancerCancer Gene Therapy, 2004
- Inducible Silencing of KILLER/DR5 In vivo Promotes Bioluminescent Colon Tumor Xenograft Growth and Confers Resistance to Chemotherapeutic Agent 5-FluorouracilCancer Research, 2004
- Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cellsOncogene, 2004
- Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cellsPhytotherapy Research, 2002
- Caspase-10 is an initiator caspase in death receptor signalingProceedings of the National Academy of Sciences, 2001
- TRAIL Causes Cleavage of Bid by Caspase-8 and Loss of Mitochondrial Membrane Potential Resulting in Apoptosis in BJAB CellsBiochemical and Biophysical Research Communications, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAILScience, 1997
- Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesisCancer Letters, 1994
- Inhibition of the mutagenicity of bay-region diol-epoxides of polycyclic aromatic hydrocarbons by phenolic plant flavonoidsCarcinogenesis: Integrative Cancer Research, 1983